Pipeline Peak 2: Leveraging AI From Human Derived Data to Identify Drug Leads & Establish Efficacy for IPF & NASH

Time: 9:00 am
day: Day Two


  • Highlighting preclinical validation for two compounds with novel MOAs, TXR-1002 and TXR-1007, for IPF and one compound with a novel MOA, TXR-612, for NASH, that show significant efficacy in preclinical models and excellent tolerability